#AI reads Urine# Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid-resistant immune thrombocytopenia
Published 20 August, 2025
The study focuses on paediatric steroid-resistant immune thrombocytopenia (ITP). Using urine proteomics, it analyzed urine samples from 37 patients (17 rituximab (RTX) responders and 20 non-responders) and 40 healthy controls. It identified 78 differential proteins before treatment and 67 after treatment. Responders were associated with humoral immunity and complement activation, while non-responders showed stronger connections to cellular immunity and glycolysis. After validation, KLK6 and FUBP1 were found to be biomarkers for predicting RTX efficacy (AUC 0.98), and a model consisting of 5 proteins including HK1 and FUBP1 could effectively monitor post-treatment effects (AUC 1.00). These findings help understand the mechanism of RTX and promote personalized therapy.
Br J Haematol. 2025 Aug 8. doi: 10.1111/bjh.70072.
Youhe Gao
Statement: During the preparation of this work the author(s) used Doubao / AI reading for summarizing the content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.
For earlier AI Reads Urine articles：